J&J’s chal­lenge to As­traZeneca in lung can­cer takes flight with PhI­II PFS win

John­son & John­son said that its com­bi­na­tion treat­ment staved off can­cer pro­gres­sion for longer than As­traZeneca’s block­buster Tagris­so as a first op­tion for pa­tients with a form of ad­vanced lung can­cer.

In the Phase III MARI­POSA study, J&J pit­ted its bis­pe­cif­ic an­ti­body Ry­bre­vant and ty­ro­sine ki­nase in­hibitor laz­er­tinib against Tagris­so alone. The study in­clud­ed 1,074 pa­tients with lo­cal­ly ad­vanced or metasta­t­ic EGFR-mu­tat­ed non-small cell lung can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER